ArtVentive Medical Group, Inc. (OTCBB: AVTD) announced today that the Company has conducted its First Human Clinical Study with its EOS Peripheral vascular occlusion device. The study involved six male patients who had conditions related to venous peripheral disease, known as varicocele. The patients were infertile and suffered pain in the low pelvic area requiring venous occlusion of their spermatic or gonadal veins. The trial was pivotal in meeting the Company's goals, with a reported 100% acute procedural and clinical success providing a predictable, immediate occlusion of all targeted blood vessels. The study demonstrated the device's accuracy, safety and effectiveness.

The Study was performed by Dr. Adrian Ebner, of the Italian Clinic in Asuncion, Paraguay and Dr. Anthony Venbrux, Director of the Vascular and Interventional Radiology Division at the George Washington University Medical Center, located in Washington, DC.

Dr. Rudakov, President and Chief Technology Officer of ArtVentive Medical Group, Inc., was present during the trial and stated that, "The performance of the device showed the exceptional and unique advantage for occlusion of vessels in a wide spectrum of peripheral vascular applications. This is a noted milestone in the Company's quest to achieve its European commercialization of the EOS device."

About ArtVentive Medical Group, Inc.

ArtVentive Medical Group, Inc., with corporate headquarters in Carlsbad, California, is an innovative, multi-faceted medical device corporation committed to developing, manufacturing and marketing a family of endoluminal occlusion devices (EOS).

ArtVentive Medical Group, Inc., through its proprietary technology, has developed unique minimally invasive occlusion devices and procedures, bringing the current interventional image guided techniques to a new level of sophistication, resolving significant and unaddressed health issues. The EOS is a catheter based self-expandable device, used to achieve permanent or temporary (reversible) occlusion of blood vessels or other tubular structures in a human body. The patented revolutionary device will serve in many cases as a safe and reliable alternative to major surgery. ArtVentive's EOS device targets a substantive market demand in several major clinical areas, including women's health, peripheral and neurologic vascular disorders and interventional cardiology procedures.

The EOS device is currently being evaluated in clinical investigations and has not yet been approved by regulatory authorities for commercialization.

More information about the Company can be found at www.artventivemedical.com.

Forward-Looking Statements

This news release may include "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements are based on the beliefs by our management as well as assumptions made by and information currently available to the company. These statements reflect the company's current views with respect to future events and are not guarantees of future performance. These statements may involve risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the said forward-looking statements. These factors include, among other things, the company's periodic reports filed with the Securities and Exchange Commission. You should not put undue reliance on any forward-looking statements. Except as required by law, the company does not undertake any obligation to update or revise these forward-looking statements to reflect new information or events or circumstances that occur after the date of this news release or to reflect the occurrence of unanticipated events or otherwise. Readers are advised to review the company's filings with the Securities and Exchange Commission which are available from the SEC's EDGAR database at www.sec.gov, at various SEC reference facilities in the United States.

ArtVentive Medical Group, Inc.
H.J. (Jim) Graham, CEO
760-471-7700
hjgraham@artventivemedical.com